secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001564590-22-026689
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.
- Cash, cash equivalents and short-term investments at $169M as of June 30, 2022.
- VK2809 Phase 2b VOYAGE study for NASH/fibrosis; enrollment completion expected in 4Q 2022.
- Phase 1 study of dual GLP-1/GIP agonist VK2735 ongoing; initial results expected by year-end 2022.
- FDA clinical hold on VK0214 Phase 1b for X-ALD lifted; dosing to resume, data expected 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/0001564590-22-026689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/vktx-8k_20220727.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-026689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer